

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Cancelled).
2. (Cancelled).
3. (Cancelled).
4. (Cancelled).
5. (Cancelled).
6. (Cancelled).
7. (Cancelled).
8. (Currently Amended) A compound of the formula
N-1-[(4-chlorophenyl)]-N-2-{[4-(2-{dimethylaminomethyl}phenyl)phenyl]-
}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-ethynylphenyl)]-N-2-{[4-(2-{dimethylaminomethyl}phenyl)-
phenyl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-chlorophenyl)]-N-2-{[2-fluoro-4-(2-{dimethylaminomethyl}-
phenyl)phenyl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-ethynylphenyl)]-N-2-{[2-fluoro-4-(2-{dimethylaminomethyl}-
phenyl)phenyl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-chlorophenyl)]-N-2-[(4-(2-dimethylaminomethylimidazol-1-yl)-
phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(4-(2-dimethylaminomethyl-imidazol-1-yl)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(2-dimethylaminomethyl-imidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(2-dimethylamino-methylimidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,


N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

or pharmaceutically usable derivatives, salts or stereoisomers thereof, including mixtures thereof in all ratios.

9. (Currently Amended) Process for the preparation of compounds of the formula I



in which

R denotes Hal, $-\text{C}\equiv\text{C}-\text{H}$, $-\text{C}\equiv\text{C}-\text{A}$ or OA,


R^1 denotes H, $=\text{O}$, Hal, A, OH, OA, A-COO-, Ph-(CH₂)_n-COO-, cycloalkyl-(CH₂)_n-COO-, A-CONH-, A-CONA-, Ph-CONA-, N₃, NH₂, NO₂, CN, COOH, COOA, CONH₂, CONHA, CON(A)₂, O-allyl, O-propargyl, O-benzyl, $=\text{N}-\text{OH}$, $=\text{N}-\text{OA}$ or $=\text{CF}_2$,

R^2 denotes H or A,

Ph denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OA, OH or Hal,

R^3 denotes H, Hal or A,

R^4 denotes $-\text{C}_6\text{H}_4-(\text{CH}_2)_n-\text{NR}^5\text{R}^5$, $-\text{C}(=\text{NR}^5)\text{NR}^5\text{R}^5$,



R^5, R^5 each, independently of one another, denote H or A,


A denotes unbranched, branched or cyclic alkyl having 1-12 C atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

Hal denotes F, Cl, Br or I,


n denotes 0, 1, 2 or 3,

or pharmaceutically usable derivatives, salts and stereoisomers thereof, comprising reacting

a) a compound of the formula II




with a chloroformate derivative to give an intermediate carbamate derivative,
subsequently reacting said intermediate with a compound of the formula III



or


b) reacting a compound of the formula III

with a compound of the formula IV




or

c) reacting a compound of the formula V



with a compound of the formula VI



in which

L denotes Cl , Br , I or a free or reactively functionally modified OH group

and/or converting

a base or acid of the formula I into one of its salts.

10. (Cancelled)

11. (Cancelled).

12. (Currently Amended) A pharmaceutical composition comprising at least one compound according to Claim 8 ± and/or pharmaceutically usable derivatives, salts and stereoisomers thereof, including mixtures thereof in all ratios, and pharmaceutically acceptable excipients and/or adjuvants.
13. (Cancelled).
14. (Previously Presented) A method for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tinnitus, tumours, tumour diseases and/or tumour metastases, comprising administering to a host in need thereof an effective amount of a compound of claim 8 and/or pharmaceutically useable derivatives, salts or stereoisomers thereof.
15. (Cancelled)
16. (Cancelled).
17. (New): A compound according to claim 8, wherein said compound is N-1-[(4-chlorophenyl)]-N-2-[[4-(2-{dimethylaminomethyl}phenyl)phenyl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.
18. (New): A compound according to claim 8, wherein said compound is N-1-[(4-ethynylphenyl)]-N-2-[[4-(2-{dimethylaminomethyl}phenyl)phenyl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.
19. (New): A compound according to claim 8, wherein said compound is N-1-[(4-chlorophenyl)]-N-2-[[2-fluoro-4-(2-{dimethylaminomethyl}phenyl)phenyl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

20. (New): A compound according to claim 8, wherein said compound is N-1-[(4-ethynylphenyl)]-N-2-[[2-fluoro-4-(2-{dimethylaminomethyl}phenyl)phenyl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

21. (New): A compound according to claim 8, wherein said compound is N-1-[(4-chlorophenyl)]-N-2-[(4-(2-dimethylaminomethylimidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

22. (New): A compound according to claim 8, wherein said compound is N-1-[(4-ethynylphenyl)]-N-2-[(4-(2-dimethylaminomethyl-imidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

23. (New): A compound according to claim 8, wherein said compound is N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(2-dimethylaminomethyl-imidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

24. (New): A compound according to claim 8, wherein said compound is N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(2-dimethylaminomethylimidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

25. (New): A compound according to claim 8, wherein said compound is N-1-[(4-chlorophenyl)]-N-2-[(4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

26. (New): A compound according to claim 8, wherein said compound is N-1-[(4-ethynylphenyl)]-N-2-[(4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

27. (New): A compound according to claim 8, wherein said compound is N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

28. (New): A compound according to claim 8, wherein said compound is N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

29. (New): A compound according to claim 8, wherein said compound is N-1-[(4-chlorophenyl)]-N-2-[(4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

30. (New): A compound according to claim 8, wherein said compound is N-1-[(4-chlorophenyl)]-N-2-[(4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

31. (New): A compound according to claim 8, wherein said compound is N-1-[(4-ethynylphenyl)]-N-2-[(4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

32. (New): A compound according to claim 8, wherein said compound is N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.